Many patients with heart failure should receive an aldosterone receptor antagonist, ie, either
spironolactone (Aldactone) or the newer agent eplerenone (Inspra)--in addition to an …

The aldosterone receptor antagonists (ARAs) spironolactone (Aldactone) and eplerenone
(Inspra) have become part of standard medical therapy for heart failure, having shown …

Standard therapy for heart failure (HF) consists of badrenergic–blocking agents or b-
blockers and either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin …

Aldosterone is a mineralocorticoid hormone synthesized by the adrenal glands that has
several regulatory functions to help the body maintain normal volume status and electrolyte …

Activation of the renin-angiotensin-aldosterone system (RAAS) is a prominent feature of left
ventricular dysfunction and plays an important role in the progression of chronic heart …

Background Aldosterone antagonists have been proven to be beneficial in severe heart
failure (HF) as a result of systolic dysfunction. We sought to determine if there is a disparity in …

The role of aldosterone in the pathophysiology of congestive heart failure (CHF) has long
been recognized. The recent RALES (Randomized Aldactone Evaluation Study) trial …

Opinion statement Heart failure is associated with neurohormonal activation, including
activation of the renin-angiotensin-aldosterone system. Plasma aldosterone levels are …

Randomized controlled trials demonstrate the efficacy of aldosterone receptor antagonists
(spironolactone and eplerenone) as a useful pharmacologic intervention specifically in …

The recent publication of the Eplerenone in Mild Patients Hospitalization and Survival Study
in Heart Failure (EMPHASIS-HF) has affirmed the important role of aldosterone-receptor …